<div id="readability-page-1"><div><p>The United States market has shown robust performance, rising 3.4% over the last week and 35% over the past year, with earnings projected to grow by 16% annually. In such a thriving market, identifying stocks with strong potential for growth often involves looking beyond well-known names to those that might not be on every investor's radar. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies that could offer surprising value and stability when backed by solid financial health.</p><h3>Top 10 Penny Stocks In The United States</h3><div><table><tbody><tr><td><strong>Name</strong></td><td><strong>Share Price</strong></td><td><strong>Market Cap</strong></td><td><strong>Rewards &amp; Risks</strong></td></tr><tr><td>WM Technology (MAPS)</td><td>$0.3869</td><td>$62.22M</td><td>✅ 3 ⚠️ 5 View Analysis &gt;</td></tr><tr><td>LexinFintech Holdings (LX)</td><td>$2.33</td><td>$378.59M</td><td>✅ 3 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>Tuniu (TOUR)</td><td>$0.7401</td><td>$84.55M</td><td>✅ 2 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>Information Services Group (III)</td><td>$3.11</td><td>$194.03M</td><td>✅ 3 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>Golden Growers Cooperative (GGRO.U)</td><td>$5.00</td><td>$77.45M</td><td>✅ 2 ⚠️ 5 View Analysis &gt;</td></tr><tr><td>Niagen Bioscience (NAGE)</td><td>$4.74</td><td>$376.36M</td><td>✅ 3 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>LifeVantage (LFVN)</td><td>$4.35</td><td>$52.95M</td><td>✅ 4 ⚠️ 3 View Analysis &gt;</td></tr><tr><td>Village Farms International (VFF)</td><td>$2.88</td><td>$307.33M</td><td>✅ 5 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>SIGA Technologies (SIGA)</td><td>$7.80</td><td>$328.13M</td><td>✅ 2 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>Marine Petroleum Trust (MARP.S)</td><td>$5.00</td><td>$10M</td><td>✅ 2 ⚠️ 4 View Analysis &gt;</td></tr></tbody></table></div><p>Click here to see the full list of 349 stocks from our  US Penny Stocks screener.</p><p>Let's uncover some gems from our specialized screener.</p><h2>Telos (TLS)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> Telos Corporation, along with its subsidiaries, offers cyber, cloud, and enterprise security solutions both in the United States and internationally, with a market cap of approximately $325.26 million.</p><p><strong>Operations:</strong> The company generates revenue through its Secure Networks segment, which accounts for $15.21 million, and its Security Solutions segment, contributing $149.6 million.</p><p><strong>Market Cap:</strong> $325.26M</p><p>Telos Corporation, with a market cap of US$325.26 million, has shown significant revenue growth but remains unprofitable, posting a net loss of US$36.55 million for 2025. Despite this, the company is debt-free and its short-term assets exceed both short and long-term liabilities. Recent developments include the expansion of TSA PreCheck enrollment services and achieving FedRAMP High authorization for its Xacta Cyber GRC platform, enhancing its risk management capabilities. Telos's share buyback program reflects confidence in its valuation as it trades significantly below estimated fair value despite insider selling concerns.</p><ul><li>Click here to discover the nuances of Telos with our detailed analytical financial health report.</li><li>Assess Telos' future earnings estimates with our detailed growth reports.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf8637cb-0cc5-4c04-9e00-f13f14bb852e/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf8637cb-0cc5-4c04-9e00-f13f14bb852e/chart/debt-equity-history-analysis"/><figcaption>TLS Debt to Equity History and Analysis as at Apr 2026</figcaption></figure><h2>InflaRx (IFRX)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing C5a inhibitor technology in Germany and the United States, with a market cap of $82.41 million.</p><p><strong>Operations:</strong> InflaRx generates its revenue primarily from its Pharmaceuticals segment, which amounts to €0.03 million.</p><p><strong>Market Cap:</strong> $82.41M</p><p>InflaRx, with a market cap of $82.41 million, is a pre-revenue biopharmaceutical company focusing on C5a inhibitor technology. The company's recent in vitro findings highlight izicopan's low risk for drug-drug interactions, enhancing its pharmacological profile. However, InflaRx faces challenges with its financial stability as auditors have expressed doubts about its ability to continue as a going concern. While the Phase 3 trial for vilobelimab in pyoderma gangrenosum showed some promising results, it was terminated early due to futility concerns. The company remains debt-free and has sufficient cash runway for over a year if current conditions persist.</p><ul><li>Get an in-depth perspective on InflaRx's performance by reading our balance sheet health report here.</li><li>Gain insights into InflaRx's outlook and expected performance with our report on the company's earnings estimates.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/15298cd0-d408-4bf2-904a-9edef263d494/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/15298cd0-d408-4bf2-904a-9edef263d494/chart/debt-equity-history-analysis"/><figcaption>IFRX Debt to Equity History and Analysis as at Apr 2026</figcaption></figure><h2>Endava (DAVA)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Endava plc, along with its subsidiaries, offers technology services across North America, Europe, the United Kingdom, and internationally, with a market cap of $234.62 million.</p><p><strong>Operations:</strong> The company generates £743.90 million in revenue from its computer services segment.</p><p><strong>Market Cap:</strong> $234.62M</p><p>Endava, with a market cap of US$234.62 million, is navigating challenges as it remains unprofitable with increasing losses over the past five years. Despite trading at a good value compared to peers and maintaining satisfactory debt levels, its earnings are forecast to grow significantly at 98.6% per year. Recent guidance indicates a slight revenue decline for fiscal 2026, while strategic partnerships aim to enhance AI-native delivery capabilities through Dava.Flow™?. The company has also completed significant share buybacks, reducing outstanding shares by 13.59%, which may influence shareholder value positively amidst ongoing operational improvements.</p><ul><li>Dive into the specifics of Endava here with our thorough balance sheet health report.</li><li>Gain insights into Endava's future direction by reviewing our growth report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a31bb721-eaae-48a2-abe6-f764585ca399/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a31bb721-eaae-48a2-abe6-f764585ca399/chart/debt-equity-history-analysis"/><figcaption>DAVA Debt to Equity History and Analysis as at Apr 2026</figcaption></figure><h2>Key Takeaways</h2><ul><li>Click through to start exploring the rest of the 346   US Penny Stocks now.</li><li>Seeking Other Investments? Find companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Endava might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

IFRX

DAVA

MAPS

<p>The U.S. market has risen 3.4% in the past week and 35% over the last year, with earnings expected to grow by 16% annually. This environment encourages investors to explore penny stocks, which can offer surprising value. Notable penny stocks include WM Technology, LexinFintech, and Telos Corporation, which, despite being unprofitable, shows potential due to its debt-free status and revenue growth. InflaRx, a clinical-stage biopharmaceutical company, faces financial stability challenges but remains debt-free. Endava, while unprofitable, forecasts significant earnings growth and has engaged in share buybacks to enhance shareholder value.</p>

April 2026 Penny Stocks To Watch For Potential Growth